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Abstract 
 
         Effective  protection  against  pathogenic  bacteria  requires  both  mucosal  and  systemic 
immune responses. Intranasal administration of antigens induces these responses. The protective 
effect of intranasal immunization with different formalin-inactivated bacterial lysates in albino 
mice  was  evaluated.  This  study  used  formalin  inactivated  lysate  of  each  of  the  following 
Escherichia  coli  ,  Pseudomonas  aeroginosa  ,Salmonella  typhi  ,  Shigella  flexeneri  , 
Staphylococcus  aureus  ,  Bacillus  subtilis    and  mixed  bacterial  lysates.  The  lysate  was 
administered intranasally (5µl/ nostril) once daily for seven consecutive days.  The results of 
this study recorded some changes in peripheral blood total and differential leucocytic counts , 
peritoneal fluid and bone marrow lymphocytic percentages . Spleen and thymus weight changes 
were reported under the effect of Salmonella typhi lysate, Shigella flexeneri lysate and Staph. 
aureus lysate. The level of immunoglobulin G (Ig G) was assessed in serum, bronchial lavage 
and nasal bed harvest. The levels of Ig G were significantly elevated in the three determinants, 
suggesting an efficient immunostimulatory effect of bacterial lysates. Some of these levels were 
exceeding 2-3 folds of that of the control group. Histopathological studies recorded changes in 
some reticuloendothelial system organs  including the liver, spleen  and thymus gland,  besides, 
some  changes  were  also  observed  in  the  lung  and  bronchi  under  the  effect  of  intranasal 
vaccination. This  study supports  the  immunoprotective effect  of intranasal  vaccination,  using 
bacterial lysates. 
 
Introduction 
     
         Effective  protection  against  respira-
tory tract pathogens requires both mucosal 
and systemic immune responses. Intranasal 
administration  of  antigens  induces  these 
responses. Intranasal immunization is more 
effective  than  oral  immunization,  as  it 
generates  an  earlier  and  stronger  mucosal 
immune  response  (Hirabayashi  et  al., 
1990).  Inactivated  whole  bacterial  cell 
suspensions are probably the most common 
type  of  vaccine  used  in  domestic  animals. 
These  vaccines  proved  to  be  extremely 
effective and safe to use even in young or 
pregnant  animals  (Bey  et  al.,  1997). 
Havlasova et al. (2002), have detected more 
than  80  different  immunorelevant  antigens 
came  from  whole  cell  bacterial  lysate  of 
Francisella  tularenis.  Such  antigens  are 
responsible  for  immune-omodulator, 
immunostimulant  activities  of  whole  cell 
bacterial lysates. 
         Bacterial  vaccines  can  be  applied 
effectively through the intranasal route (Orr 
et  al.,  1993  and  Ambrosino,  1996). 
Bonenfant et al. (2001) mentioned that the 
ability for increasing systemic and mucosal 
responses  may  be  of  great  importance  for 
the  development  of  an  efficient  vaccine. 
Furthermore,  the  intranasal  route  requires 
less  antigen  than  the  oral  route  because 
there is much less proteolytic activity in the 
nasal  cavity.  This  route  effectively 
promotes  the  production  of  both  systemic 
and  mucosal  immune  responses  to  the 
antigen  (Wu  and  Russell,  1997).  Di- 
Tommaso et al. (1996) and Partidos et al. 
(1999),  showed  that  bacterial  enterotoxins 
act as   appropriate   mucosal      adjuvants 
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following oral and intranasal immunization 
with various antigens that trigger local and 
systemic  immune  responses.  These  adjuv-
ants  have  also  been  used  with  bacterial 
antigen  and  protect  against  infection  with 
Helicobacter  pylori  after  oral  vaccination 
(Kim et al., 1999) and intragastric vaccin-
ation (Marchetti et al., 1998) . 
         Gawlik and Danek (1999), mentioned 
that  bacterial  lysates  act  as  immunom-
odulators-  immunoprophylactics  in  chronic 
respiratory  diseases.  Rutishauser  et  al. 
(1998)  and  Grevers  et  al.  (2000)    used 
polyvalent bacterial lysates in patients with 
recurrent  respiratory  tract  infections  where 
an oral immunomodulator consisting of the 
antigens  of  seven  bacteria  commonly 
involved  in  respiratory  tract  infections  has 
been developed for the induction of specific 
and  non-specific  immune  responses  of  the 
mucosa  associated  lymphoid  tissue. 
Jakobsen  et  al.  (1999)  showed  that  the 
intranasal immunization with Streptococcus 
pneumo-niae  polysaccharide  conjugate 
vaccine could protect mice against invasive 
pneumococcal  infections.  The  use  of  nasal 
delivery of an acellular Bordetella pertussis 
vaccine,    could  effectively  protect  against 
Bordetella  pertussis  infection  through  the 
activation of Th1 and Th2 cells. Greenbaum 
et al. (2004) showed that the levels of muc-
osal Ig  A and  serum Ig  A and  Ig G  were 
elevated  in  response  to  intranasal  adminis-
tration  of  inactivated  anti-  influenza 
vaccine.   
         This  study  aimed  to  evaluate  the 
immunoprotective effect of daily  intranasal 
lysate  vaccination  for  seven  consecutive  
days using lysates of each of the following: 
Escherichia coli , Psudomonas aeroginosa , 
Salmonella  typhi,  Shigella  flexeneri  , 
Staphylococcus aureus  and mixed bacterial 
lysates. 
  
Material And Methods 
 
Bacteria:  
1.  Escherichia coli  (CAIM- 1357). 
2.  Pseudomonas  aeroginosa  ( 
clinicaly isolated). 
3.  Staphylococcus  aureus 
(CAIM- 1352). 
4.  Salmonella typhi. 
5.  Shigella sp. (NMRO). 
6.  Bacillus  subtilis  (CAIM- 
1007). 
         Bacterial  strains  used  in  this  study 
were  obtained  from  the  Microbiology 
Department in NODCAR. 
 
Animals: 
         Eighty male albino mice weighing 18- 
25 gm  each were used in the present study. 
The animals were obtained from the animal 
house  of    NODCAR.  The  animals  were 
divided into the following  groups, control, 
placebo and intranasal vaccinated . 
 
Intranasal vaccinated group: 
         Bacterial  lysate  vaccinated  group 
which  recived  Esch.  coli  lysate,  Ps. 
aeroginosa lysate, Staph. aureus lysate and 
mixed bacterial  lysates  (Corthesy-  Theulaz 
et  al.,  1998  and  Bonenfant  et  al.,  2001). 
Each animal received 5 μl of the vaccine in 
each  nostril,  once  daily  that  was  repeated 
for  seven  consecutive  days  (Ruedl  et  al., 
1994 and Bennet- Guerrero et al., 2000). 
 
Bacterial lysate preparation : 
         A  24  hours  bacterial  growth  of 
Escherichia coli, Pseudomonas aeroginosa, 
Salmonella  typhi,  Staphylococcus  aureus 
and Bacillus subtilis that had viable counts 
2.72x10
8 , 7.56x10
8 , 13.91x10
8 , 7.33x10
8 
and    2.91x10
8  CFU/ml  respectively  was 
used to prepare the bacterial lysate used in 
this  study.  A  volume  of  25  ml  of  the  24 
hours bacterial growth was lysed using high 
speed  4000  rpm  homogenizer  [  variable 
GKH-  GT  MOTOR  control-  Glas-  Col 
(USA) ]. 1/100  v/v of  10%   formalin  was  
added  (Okamoto  et  al.,  2004)  .    Then  a 
subculture  of  the  lysates  on  nutrient  agar     
(Oxoid)  were  observed  for  24  hours  to 
ensure    that    the  bacterial  lysates  did  not 
include  any  viable  bacteria    (Hugo  and 
Russel,  1993  and  Raghavan  et  al.,  2002). 
Mixed bacterial lysates were prepared from 
equal  volumes  of  the  different  bacterial 
lysates  used  in  this  study  (Ruah  et  al., 
2001). 
 
Nasal bed harvest : 
         The  nasal-associated  lymphoid  tissue 
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using  an  automatic  cell  harvester,  high 
speed  homogenizer  (Variable  GKH-GT 
MOTOR  control-  Glass-  Col.  USA).  One 
gram  of  the  dissected  nasal  bed  was 
harvested in 1 ml of phosphate buffer saline 
( PBS ), then centrifuged aseptically at 4000 
rpm for 15 mins. to separate the supernatant 
that  was  kept  frozen  until  assayed  for 
estimating  the  level  of  Ig  G  (Bonenfant  et 
al, 2001). 
 
Bronchial lavage : 
         Lung  washes  were  obtained  by 
performing bronchial lavage where repeated 
flushing and aspiration of 1 ml of phosphate 
buffer saline (PBS) was done under sterile 
conditions.  The  wash  was  centrifuged  at 
4000 rpm for 15 mins. to remove any cell 
debris.  The  supernatant  was  aspirated  and 
kept frozen until assayed for estimating the 
level of Ig G (Williamson et al., 2000  and 
Bonenfant et al., 2001).  
 
Immunoglobulins assay : 
         Serum  was  obtained  from  control 
animals  and  bacterial  lysates  treated  ani-
mals. Serum was divided into aliquots and 
stored  in  the  freezer  until  processed. 
Immunoglobulins  G  and  M  assays  were 
done  using  [  Mouse  Immunoglobulin  ‘LL’ 
NANORID-  BIND  A  RID-  NANORID 
PRODUCTS-  immundiff-usion  plates 
which  were  supplied  by  THE  BINDING 
SITE LIMITED Co. UK]. The precipitation 
rings were measured to an accuracy of 0.1 
mm . The  assay results were obtained from 
the  calibration  table    values  given  by  the  
manufacturer (Fahey and Mc Kelvey, 1965 
and Sadeq et al., 1992). 
 
Haematology assays: 
         About  0.25  ml  blood  samples  were 
drawn  by  capillary  tubes  from  the  retro-
orbital  plexus  from  each  mouse,  being 
added  to  EDTA  for  peripheral  blood  total 
leucocytic  count  and  differntial  leucocytic 
count. Direct smears were withdrawn from 
the peritoneal fluid for peritoneal fluid total 
and  differential  leucocytic  counts.  Bone 
marrow  smears  that  were  obtained    from  
the  femur bone were  spreaded  for  bone 
marrow  lymphocytic    count.    Leishman  
stain  was  used for the different leucocytic 
counts. 
 
Physiological parameters: 
         The total  body  weight  (T)   of    each  
animal  was   recorded, followed by determ-
ining  the  liver(L),  spleen(S)  and  thymus 
(Th) weights and  the (L+S+Th)/T ratio was 
determined. 
 
Histopathological examination : 
         The liver, spleen, thymus gland, lung 
and  tracheae  were  collected  soon  after 
slaughter  and  fixed  in  10%  formalin, 
blocked in paraffin wax, cut in  sections 5 
µm  and  stained  with  haematoxyline  and 
Eosin (H&E) for microscopic examination. 
         The results  were  statistically evalu-
ated    using    the  student  t-  test  where  the 
significance  of  the  differences  between 
treated  and  respective  control  groups  was 
analysed (Goldstein, 1964) . 
 
Results 
 
         The results demonstrated in table (1) 
cleared that bacterial lysate daily vaccinated 
animal  groups  showed  increased  total 
leucocytic  count  except  in  case  of  
Salmonella  typhi  lysate.  This  leucocytic 
response  was  significant  on  the  use  of 
mixed  bacterial  lysates  at  P  <  0.001,  that 
was associated  with significant  increase  of 
neutrophilic count at P < 0.05. Escherichia 
coli  lysate  caused  significant  increase  of 
neutrophilic count that was associated with 
a significant drop of lymphocytic count. 
         Table  (2)  showed  that  Salmonella 
typhi,  Shigella  flexneri  ,  Pseudomonas 
aeroginosa  and  mixed  bacterial  lysates 
intranasal  vaccination  caused  a  significant 
drop of peritoneal fluid neutrophilic counts 
that  were  associated  with  a  significant 
lymphocytic  response  and  non-  significant 
drop in monocytic and eosinophilic counts 
         Table (3) showed that mixed bacterial 
lysates caused an increase of bone marrow 
lymphocytic  percentage  in  intranasally 
vaccinated animals, while Salmonella typhi 
lysate  intranasal  vaccination  induced  a 
significant  drop  of  bone  marrow  lympho-
cytic percentage at P < 0.001. Hanaa A. Mansour 
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         Table  (4)  illustrated  a  splenomegalic 
effect  of  Salmonella  typhi  and  Shigella 
flexeneri  lysates  intranasal  vaccination. 
This  splenomegalic  effect  of  Shigella 
flexeneri  lysate  was  associated  with  a 
significant increase of thymus weight at P < 
0.01, similar thymus response was detected 
on the use of Staph. aureus lysate intranasal 
vaccination. 
         Table (5) and Fig. (5) showed that the 
different  bacterial  lysates  caused  a 
significant increase in the  serum, nasal bed 
harvest  and  bronchial  lavage  Ig  G  levels. 
This  increase  was  non-  significant  in  the 
serum  of  the  animals  vaccinated  with 
Pseudomonas  aeroginosa  lysate,    while 
those  vaccinated  with  Esch.  coli  lysate,  
showed a non- significant drop in the level 
of seum Ig G.         
 
Histopathological analysis : 
         The  liver  of  mice  which  were 
vaccinated intranasally with Esch. coli and 
Ps.  aerog.  lysate  showed  activation  of 
Kupffer  cells  (Figs.  1-  3&4).  That  activa-
tion  of  Kupffer  cells  was  associated  with 
mononuclear  cellular  infiltration  in  the 
periportal  areas  in  the  animals  vaccinated 
with  Shig.  flexeneri  lysate,  Staph.  aureus 
lysate  and mixed bacterial lysates (Fig. 1- 
6,7&8). Fig. 1-7 showed lymphocytic infilt-
ration  associated  with  mild  degenerative 
changes  in  the  portal  area  and  ruptured 
endothelial  lining  of  hepatic-portal  vein. 
Those  vaccinated  with  Salm.  typhi  lysate 
revealed  congestion  of  central  veins  and 
portal  blood  vessels,  inflammatory  lymph-
ocytic  infiltration  and  some  cells  showed 
hepatocellular degeneration (Fig. 1-5). 
         The  spleen  of  mice  treated  intran-
asally  with  Ps.  aerog.  lysate  and  Staph 
aureus  lysat    showed  congested  sinusoidal 
spaces  filled  with  erythrocytes  and  early 
signs  of  inflammation  with  mononuclear 
and  polymorphonuclear  leucocytes,  stagn-
ation  of  blood  within  splenic  vessels  that 
infiltrated  the  red  pulp  could  be  detected 
(Fig.  2-  4&7).  Bacterial  lysates  caused  a 
considerable  increase  in  the  white  pulp, 
specially  the  outer  part  of  the  periarterial 
lymphocyte  sheath  (PALS),  where  
abundant lymphoid cells appeared. The red 
pulp contained aggrega-tions of large nuclei 
varying  considerably  in  size  (Fig.  2-  4,6 
&8). The spleen  of mice that received Shig. 
flexeneri lysate showed heavy lymph-ocytic 
infiltration  of  mature  lymphocytes,  plasma 
cells and macrophages in red pulp (Fig. 2-
6).  The  spleen  of  mice  treated  with  Salm. 
typhi  lysate  showed  degenerative  changes. 
There  was  a  reduction  in  the  overall 
cellularity of follicles and number of mature 
lymphocytes.  Megakaryocytes  were  readily 
lost  and  myelopoiesis  appeared  virtually 
reduced (Fig. 2- 5). 
         The  thymus  obtained  from  animals 
vaccinated  with  Esch.  coli  lysate  showed 
degenerated cells  in  cortex  and  medulla  of 
the  thymus  gland  and  reduced  Hassal’s 
corpuscles (Fig. 3-3), other bacterial lysates 
caused heavy  lymphocytic infiltration  (Fig. 
3-4,5,6,7&8). The thymus sections obtained 
from mice vaccinated intranasally with  Ps. 
aerog.  lysate  showed  some  cortical  and 
medulla cells that appeared  faintly stained, 
also  corticomedullary  differentiation  was 
indistinct  (Fig.  3-4).The  thymus  gland 
section  obtained  from  animals  received 
Shigella  flexeneri  lysate  showed  some 
vaculated cells in medulla  and  cortex,  also  
bizarre    cells      or    their  debris  could  be 
detected (Fig. 3-6). 
         Lung  tissues  obtained  from  bacterial 
lysates  intranasally  vaccinated  animals 
showed  increased  lymphocytic  and  cellular 
infiltrations. This infiltration was markedly 
heavy around the wall of the bronchi in the 
animals treated with Ps. aerog. lysate  (Fig. 
4-4). Lung  sections  obtained  from  animals 
vaccinated  with  Salm.  typhi  lysate  intran-
asally  showed    mild  fluid  accumulation 
inside the alveoli and the small bronchioles 
and thickened alveolar wall associated with 
fibrosis    (Fig.  4-5).  Shig.  flexeneri  lysate 
intranasal  vaccination  caused  degenerative 
changes  in  the  lung  tissue  and  highly 
thickened  alveolar  and  bronchiolar  walls 
(Fig. 4-6). 
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Table (1): peripheral blood total and differential leucocytic counts in bacterial lysates 
intranasal daily vaccinated animals (7- days). 
 
A AN NI IM MA AL L   G GR RO OU UP P    T TO OT TA AL L   
L LE EU UC CO OC CY YT TI IC C   
C CO OU UN NT T   / /   C CM MM M   
E EO OS SI IO ON NP PH HI IL LS S   
% %   
N NE EU UT TR RO OP PH HI IL LS S   
% %   
L LY YM MP PH HO OC CY YT TE ES S   
% %   
M MO ON NO OC CY YT TE ES S   
% %   
N NO OR RM MA AL L   C CO ON NT TR RO OL L    3 39 90 00 0± ±1 17 79 91 1    1 1. .8 88 8± ±2 2. .0 01 1    4 42 2. .4 4± ±3 3. .1 1    5 54 4± ±3 3. .0 0    1 1. .9 99 9± ±0 0. .8 86 6   
P PL LA AC CE EB BO O    4 41 13 35 5± ±1 12 23 33 3    1 1. .6 67 7± ±1 1. .9 94 4    4 41 1. .3 3± ±2 2. .7 7    5 53 3. .8 8± ±4 4. .7 7    1 1. .9 96 6± ±0 0. .2 21 1   
E ES SC CH H. .C CO OL LI I   L LY YS SA AT TE E    4 44 47 71 1± ±1 16 65 55 5    1 1. .0 0± ±0 0. .9 92 2    5 53 3. .0 0± ±4 4. .1 1
* ** ** *, ,º ºº º    4 45 5. .1 1± ±3 3. .6 6* *
, ,º º    1 1. .5 5± ±0 0. .7 76 6   
S S. .   T TY YP PH HI I   L LY YS SA AT TE E    4 40 01 17 7± ±1 17 74 49 9    1 1. .6 67 7± ±0 0. .3 34 4    4 40 0. .1 1± ±2 2. .9 9    5 54 4. .7 7± ±0 0. .9 9    2 2. .8 83 3± ±0 0. .1 18 8   
S SH HI IG GE EL LL LA A   F FL LE EX XE EN NE ER RI I   
L LY YS SA AT TE E   
5 50 00 00 0± ±1 13 36 69 9    1 1. .1 17 7± ±1 1. .6 60 0    4 44 4. .7 7± ±3 3. .3 3    5 51 1. .3 3± ±2 2. .9 9    2 2. .6 67 7± ±0 0. .8 83 3   
P PS SE EU UD DO O. .   A AE ER RO OG GI IN NO OS SA A   
L LY YS SA AT TE E   
4 46 68 88 8± ±2 24 46 64 4    1 1. .5 54 4± ±0 0. .7 76 6    3 39 9. .6 6± ±3 3. .8 8    5 56 6. .5 5± ±4 4. .4 4    2 2. .1 13 3± ±0 0. .3 34 4   
S ST TA AP PH H. .   A AU UR RE EU US S   L LY YS SA AT TE E    5 51 10 00 0± ±1 18 87 73 3    0 0. .1 12 23 3± ±0 0. .3 34 4    3 38 8. .9 9± ±4 4. .9 9    5 59 9. .2 2± ±3 3. .8 8    2 2. .2 25 5± ±0 0. .9 97 7   
M MI IX XE ED D   B BA AC CT TE ER RI IA AL L   
L LY YS SA AT TE ES S   
7 73 36 67 7± ±7 72 21 1
* ** ** *, ,º ºº ºº ºº º    1 1. .5 5± ±1 1. .3 38 8    4 48 8. .5 5± ±4 4. .6 6
* *, ,
º º    4 48 8± ±4 4. .4 4    2 2. .2 25 5± ±2 2. .8 84 4   
 
*,**,*** significant at P<0.05, 0.01 and 0.001, respectively, when compared with   control group. 
º, ºº, ºº    Significant atº P<0.05, 0.01 and 0.001, respectively, when compared with placebo 
group. 
   
Table (2): Peritoneal fluid total and differential leukocytic counts in bacterial lysates-
intranasal daily vaccinated animals (7- days).  
 
A AN NI IM MA AL L   G GR RO OU UP P    T TO OT TA AL L   
L LE EU UC CO OC CY YT TI IC C   
C CO OU UN NT T   / /   C CM MM M   
E EO OS SI IO ON NP PH HI IL LS S   
% %   
N NE EU UT TR RO OP PH HI IL LS S   
% %   
L LY YM MP PH HO OC CY YT TE ES S   
% %   
M MO ON NO OC CY YT TE ES S   
% %   
N NO OR RM MA AL L   C CO ON NT TR RO OL L    2 28 80 00 0± ±1 15 56 63 3    0 0. .7 75 5± ±0 0. .8 89 9    4 48 8. .4 4± ±3 3. .3 38 8    4 49 9± ±1 1. .7 77 7    2 2± ±1 1. .1 17 7   
P PL LA AC CE EB BO O    2 29 99 94 4± ±9 94 45 5    0 0. .7 71 1± ±0 0. .6 67 7    4 49 9. .3 3± ±2 2. .7 71 1    4 48 8. .2 2± ±2 2. .5 54 4    1 1. .7 75 5± ±1 1. .0 06 6   
E ES SC CH H. .C CO OL LI I   L LY YS SA AT TE E    2 29 90 00 0± ±2 23 37 79 9    0 0. .5 5± ±0 0. .7 76 6    5 52 2± ±8 8. .5 52 2    5 58 8. .6 6± ±3 3. .7 78 8* *, ,
º ºº º    1 1± ±0 0. .7 76 6   
S S. .   T TY YP PH HI I   L LY YS SA AT TE E    2 21 13 33 3± ±9 92 20 0    0 0. .1 17 7± ±0 0. .3 38 8    3 36 6. .5 5± ±2 2. .1 17 7* ** ** *, ,
º ºº ºº ºº º    6 62 2± ±2 2. .8 83 3* ** ** *, ,
º ºº ºº ºº º    1 1. .3 33 3± ±0 0. .8 82 2   
S SH HI IG GE EL LL LA A   F FL LE EX XE EN NE ER RI I   L LY YS SA AT TE E    1 15 58 83 3± ±6 65 55 5    0 0. .1 19 9± ±0 0. .6 68 8    4 41 1± ±1 1. .7 79 9* ** *, ,
º ºº ºº ºº º    5 58 8. .5 5± ±1 1. .5 52 2* ** ** *, ,
º ºº ºº ºº º    0 0. .1 17 7± ±0 0. .4 41 1   
P PS SE EU UD DO O. .   A AE ER RO OG GI IN NO OS SA A   
L LY YS SA AT TE E   
2 22 21 16 6± ±1 18 83 39 9    1 1± ±0 0. .9 93 3    3 35 5. .5 5± ±5 5. .7 71 1* ** *, ,
º ºº ºº ºº º    6 62 2. .3 3± ±5 5. .4 42 2* ** ** *, ,
º ºº ºº ºº º    1 1. .5 5± ±0 0. .9 96 6   
S ST TA AP PH H. .   A AU UR RE EU US S   L LY YS SA AT TE E    3 30 04 40 0± ±1 13 36 62 2    0 0. .1 17 7± ±0 0. .2 28 8    4 42 2. .8 8± ±9 9. .2 25 5
º º    5 55 5± ±7 7. .6 63 3    0 0. .1 13 3± ±0 0. .5 53 3   
M MI IX XE ED D   B BA AC CT TE ER RI IA AL L   L LY YS SA AT TE ES S    2 27 79 90 0± ±1 13 38 89 9    0 0. .2 24 4± ±0 0. .2 28 8    3 39 9. .2 2± ±6 6. .7 72 2* *, ,
º ºº ºº º    6 66 6. .9 9± ±7 7. .2 21 1* ** *, ,
º ºº ºº º    1 1± ±0 0. .9 93 3   
   
*,**,***   significant at P<0.05, 0.01 and 0.001, respectively, when compared with control group. 
º, ºº, ºº              Significant atº P<0.05, 0.01 and 0.001, respectively, when compared with placebo group. 
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Table (3): Peripheral blood, peritoneal fluid and bone marrow lymphocytic percentage in 
bacterial lysates-intranasal daily vaccinated animals (7- days). 
 
A AN NI IM MA AL L   G GR RO OU UP P    P PE ER RI IP PH HE ER RA AL L   B BL LO OO OD D   
L LY YM MP PH HO OC CY YT TE ES S   % %   
P PE ER RI IT TO ON NE EA AL L   F FL LU UI ID D   
L LY YM MP PH HO OC CY YT TE ES S   % %   
B BO ON NE E   M MA AR RR RO OW W   L LY YM MP PH HO OC CY YT TE ES S   
% %   
N NO OR RM MA AL L   C CO ON NT TR RO OL L    5 54 4± ±3 3. .0 0    4 49 9± ±1 1. .7 77 7    4 49 9. .9 9± ±5 5. .1 11 1   
P PL LA AC CE EB BO O    5 53 3. .8 8± ±4 4. .7 7    4 48 8. .2 2± ±2 2. .5 54 4    4 48 8. .2 2± ±5 5. .6 63 3   
E ES SC CH H. .C CO OL LI I   L LY YS SA AT TE E    4 45 5. .1 1± ±3 3. .6 6* *, ,º º    5 58 8. .6 6± ±3 3. .7 78 8* *, ,º º    4 48 8. .1 1± ±4 4. .2 29 9   
S S. .   T TY YP PH HI I   L LY YS SA AT TE E    5 54 4. .7 7± ±0 0. .9 9    6 62 2± ±2 2. .8 83 3* ** ** *, ,º ºº ºº º    2 20 0. .3 3± ±3 3. .6 67 7* ** ** *, ,º ºº ºº º   
S SH HI IG GE EL LL LA A   F FL LE EX XE EN NE ER RI I   L LY YS SA AT TE E    5 51 1. .3 3± ±2 2. .9 9    5 58 8. .5 5± ±1 1. .5 52 2* ** ** *, ,º ºº ºº º    4 40 0. .5 5± ±3 3. .8 83 3   
P PS SE EU UD DO O. .   A AE ER RO OG GI IN NO OS SA A   L LY YS SA AT TE E    5 56 6. .5 5± ±4 4. .4 4    6 62 2. .3 3± ±5 5. .4 42 2* ** ** *, ,º ºº ºº º    5 50 0. .1 1± ±3 3. .4 43 3   
S ST TA AP PH H. .   A AU UR RE EU US S   L LY YS SA AT TE E    5 59 9. .2 2± ±3 3. .8 8    5 55 5± ±7 7. .6 63 3    3 38 8. .5 5± ±4 4. .1 14 4* *   
M MI IX XE ED D   B BA AC CT TE ER RI IA AL L   L LY YS SA AT TE ES S    4 48 8± ±4 4. .4 4    6 66 6. .9 9± ±7 7. .2 21 1* ** *, ,º ºº º    6 64 4. .1 1± ±8 8. .4 45 5* *, ,º º   
 
*,**,***      significant at P<0.05, 0.01 and 0.001, respectively, when compared with control group. 
º º, ,   º ºº º   , ,   º ºº ºº º       significant at P<0.05, 0.01 and 0.001, respectively, when compared with     placebo group. 
 
Table (4): Total body weight (T), liver (L), spleen (S) and thymus (Th) weight and L+ S+ 
Th/ T ratio in bacterial lysate-intranasal daily vaccinated animals (7- days). 
   
A AN NI IM MA AL L   G GR RO OU UP P    T TO OT TA AL L   
B BO OD DY Y   
W WE EI IG GH HT T   ( (T T) )   
I IN N   G GM MS S   
L LI IV VE ER R   ( (L L) )   
W WE EI IG GH HT T   I IN N   
G GM MS S   
S SP PL LE EE EN N   ( (S S) )   
W WE EI IG GH HT T   I IN N   G GM MS S   
T TH HY YM MU US S   ( (T TH H) )   
W WE EI IG GH HT T   I IN N   G GM MS S   
L L+ +S S+ +T TH H/ /T T   R RA AT TI IO O   
N NO OR RM MA AL L   
C CO ON NT TR RO OL L   
2 24 4. .2 2± ±3 3. .4 49 9    1 1. .1 11 1± ±0 0. .2 25 5    0 0. .1 12 23 3± ±0 0. .0 03 3    0 0. .0 04 41 1± ±0 0. .0 00 06 6    0 0. .0 05 53 3± ±0 0. .0 00 07 7   
P PL LA AC CE EB BO O    2 24 4. .9 9± ±4 4. .2 26 6    1 1. .1 18 8± ±0 0. .2 28 8    0 0. .1 12 25 5± ±0 0. .0 04 4    0 0. .0 04 4± ±0 0. .0 00 02 2    0 0. .0 05 55 5± ±0 0. .0 00 06 6   
E ES SC CH H. .C CO OL LI I   
L LY YS SA AT TE E   
2 27 7. .1 1± ±4 4. .9 99 9    1 1. .3 35 5± ±0 0. .3 36 6    1 1. .1 16 62 2± ±0 0. .0 04 4    0 0. .0 03 34 4± ±0 0. .0 00 04 4    0 0. .0 05 55 5± ±0 0. .0 00 07 7   
S S. .   T TY YP PH HI I   L LY YS SA AT TE E    2 25 5. .9 9± ±0 0. .6 64 4    1 1. .1 12 2± ±0 0. .2 22 2    0 0. .2 24 46 6± ±0 0. .0 04 4* ** ** *, ,º ºº ºº º    0 0. .0 04 43 3± ±0 0. .0 00 02 2    0 0. .0 05 54 4± ±0 0. .0 00 01 1   
S SH HI IG GE EL LL LA A   
F FL LE EX XE EN NE ER RI I   
L LY YS SA AT TE E   
2 25 5. .7 7± ±1 1. .8 81 1    1 1. .1 19 9± ±0 0. .1 18 8    0 0. .2 20 05 5± ±0 0. .0 02 2* ** ** *, ,º ºº ºº º    0 0. .0 05 52 2± ±0 0. .0 00 03 3* ** *, ,º ºº º    0 0. .0 05 56 6± ±0 0. .0 00 04 4   
P PS SE EU UD DO O. .   
A AE ER RO OG GI IN NO OS SA A   
L LY YS SA AT TE E   
2 24 4. .7 7± ±2 2. .1 16 6    1 1. .1 17 7± ±0 0. .2 24 4    0 0. .1 15 50 0± ±0 0. .0 05 5    0 0. .0 04 46 6± ±0 0. .0 00 06 6    0 0. .0 05 55 5± ±0 0. .0 01 1   
S ST TA AP PH H. .   A AU UR RE EU US S   
L LY YS SA AT TE E   
2 25 5. .8 8± ±3 3. .1 13 3    1 1. .1 13 3± ±0 0. .2 26 6    0 0. .1 13 33 3± ±0 0. .0 05 5    0 0. .0 04 49 9± ±0 0. .0 00 01 1* *, ,º º    0 0. .0 05 51 1± ±0 0. .0 00 08 8   
M MI IX XE ED D   
B BA AC CT TE ER RI IA AL L   
L LY YS SA AT TE ES S   
2 24 4. .4 4± ±2 2. .2 26 6    1 1. .1 10 0± ±0 0. .0 08 8    0 0. .1 12 25 5± ±0 0. .0 02 2    0 0. .0 04 47 7± ±0 0. .0 00 02 2    0 0. .0 05 50 0± ±0 0. .0 00 02 2   
   
*,**,*** significant at P<0.05, 0.01 and 0.001, respectively, when compared with control group. 
º, ºº , ººº  significant at P<0.05, 0.01 and 0.001, respectively, when compared with placebo group. Response Of Mice Tissues To Intranasal Bacterial Lysate ………. 
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Table (5):  Immunoglobulin G (IgG) levels using plate diffusion method in the serum, bronchial 
lavage and nasal harvest in the different bacterial lysates-intranasal treated animals 
(daily vaccinated for seven days). 
 
A AN NI IM MA AL L   G GR RO OU UP P    I IG GG G   M MG G/ /L L   
S SE ER RU UM M    B BR RO ON NC CH HI IA AL L   L LA AV VA AG GE E    N NS SA AL L   H HA AR RV VE ES ST T   
N NO OR RM MA AL L   C CO ON NT TR RO OL L    2 27 7. .2 2± ±4 4. .6 6    1 16 6. .2 2± ±3 3. .9 9    1 17 7. .3 3± ±2 2. .2 2   
P PL LA AC CE EB BO O    2 27 7. .3 3± ±4 4. .4 4    1 16 6. .5 5± ±3 3. .1 1    1 18 8. .4 4± ±1 1. .9 9   
E ES SC CH H. .C CO OL LI I   L LY YS SA AT TE E    1 19 9. .9 9± ±1 10 0. .4 4    3 36 6. .8 8± ±4 4. .9 9* ** ** *, ,º ºº ºº º    3 33 3. .9 9± ±1 1. .9 9* ** ** *, ,º ºº ºº º   
S S. .   T TY YP PH HI I   L LY YS SA AT TE E    3 35 5. .6 6± ±3 3. .5 5* *, ,º º    4 40 0. .9 9± ±4 4. .2 2* ** ** *, ,º ºº ºº º    2 23 3. .2 2± ±3 3. .1 1* *, ,º º   
S SH HI IG GE EL LL LA A   F FL LE EX XE EN NE ER RI I   L LY YS SA AT TE E    3 39 9. .7 7± ±5 5. .1 1* *, ,º º    3 34 4. .2 2± ±2 2. .9 9* ** ** *, ,º ºº ºº º    3 37 7. .3 3± ±7 7. .4 4* ** ** *, ,º ºº ºº º   
P PS SE EU UD DO O. .   A AE ER RO OG GI IN NO OS SA A   L LY YS SA AT TE E    3 36 6. .3 3± ±9 9. .6 6    3 39 9. .1 1± ±3 3. .8 8* ** ** *, ,º ºº ºº º    3 34 4. .1 1± ±1 1. .6 6* ** ** *, ,º ºº ºº º   
S ST TA AP PH H. .   A AU UR RE EU US S   L LY YS SA AT TE E    3 36 6. .8 8± ±3 3. .8 8* *, ,º º    3 30 0± ±6 6. .4 4* ** *, ,º ºº º    3 37 7± ±3 3. .6 6* ** ** *, ,º ºº ºº º   
M MI IX XE ED D   B BA AC CT TE ER RI IA AL L   L LY YS SA AT TE ES S    4 44 4. .4 4± ±3 3. .2 2* ** ** *, ,º ºº ºº º    3 36 6. .3 3± ±3 3. .7 7* ** ** *, ,º ºº ºº º    2 25 5. .4 4± ±2 2. .7 7* ** *, ,º ºº º   
 
*,**,*** significant at P<0.05, 0.01 and 0.001, respectively, when compared with control group. 
º, ºº , ººº  significant at P<0.05, 0.01 and 0.001, respectively, when compared with placebo group. 
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Fig. (1): Liver sections  showing:  1- Normal control 2- Placebo treated 3- Esch coli lysate 
4- Ps aeroginosa lysate  5- Salm typhi lysate  6- Shig flexeneri lysate  7- Staph aureus lysate  
8- Mixed bacterial lysates (H&E). X200 
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Fig. (2): Spleen sections  showing:  1- Normal control 2- Placebo treated 3- Esch coli lysate 
4- Ps aeroginosa lysate  5- Salm typhi lysate  6- Shig flexeneri lysate  7- Staph aureus lysate  
8- Mixed bacterial lysates (H&E). X200 
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Fig. (3): Thymus  sections   showing:  1-  Normal control  2- Placebo treated  3- Esch  coli 
lysate 4- Ps aeroginosa lysate  5- Salm typhi lysate  6- Shig flexeneri lysate  7- Staph aureus 
lysate  8- Mixed bacterial lysates (H&E). X200 
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Fig. (4): Lung sections  showing:  1- Normal control 2- Placebo treated 3- Esch coli lysate 
4- Ps aeroginosa lysate  5- Salm typhi lysate  6- Shig flexeneri lysate  7- Staph aureus lysate  
8- Mixed bacterial lysates (H&E). X200 
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Fig. (5): Immunoglobulin G  (IgG) levels using plate diffusion method in 
the serum, bronchial lavage and nasal bed harvest in the different 
bacterial lysates -intranasal treated animals - daily vaccinated for  7 days 
(according to table  5).
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Discussion 
 
          Bacterial  vaccines  are  those 
composed of killed bacterial products. This 
study  has  approached  the  immuno-
prophylaxis  effect  of  bacterial  vaccines 
using  the  whole  cell  bacterial  lysates. 
Goncharova  et  al.  (2002),  mentioned  that 
nasal  mucosa  in  the  olfactory  region  is 
likely to be a promising target for mucosal 
immunization.  The  use  of  oral  and 
intranasal  bacterial  vaccines  stimulate  the 
local  and  distant  effector  site  such  as  the 
intestinal mucosa and the respiratory tract, 
the microorganism can elicit an enhanced Ig 
A  response  according  to  the  concept  of  a 
common  mucosaassociated  immune  system 
(Ruedl  et  al.,  1994).  Intranasal  immuni-
zation  delivers  the  antigen  directly  to  the 
site  of  uptake  (Kuper  et  al.,  1992).  The 
stimulation  of  cells  from  the  spleen  and 
mesenteric  lymph  nodes  after  nasal 
immunization  points  to  the  existence  of  a 
common  mucosal  immune  system 
(Bonenfant et al., 2001). This may explain 
the  significant  increase  in  peritoneal  fluid 
lymphocytic  count  recorded  in  this  study 
that  was  associated  with  a  significant 
increase of  spleen and thymus weights. On 
the  use  of  mixed  bacterial  lysates,  these 
changes  were  accompanied  by  significant 
increase  of  bone  marrow  lymphocytic 
percentage.  Kiyono  et  al.  (1992)  and 
Porgador  et  al.  (1998)  found  that  cells 
stimulated in the nasal associated lymphoid 
tissue (NALT) by the antigen presented by 
antigen-presenting  cells  can  leave  this  site 
for  mucosal  effector  sites.  Nasal  immuni-
zation  triggers  pulmonary  immunity. 
Antigen administered by the nasal route can 
reach  the  trachea  area  or  dendritic  cells 
loaded with the antigen, may have migrated 
from  the  NALT  to  the  pulmonary  lymph 
nodes,  where  they  can  initiate  an  immune 
response  (Trolle  et  al.,  1999).  Intranasal 
immunization  triggers  both  mucosal  and 
systemic T and B –cell responses (Wu and 
Russell,  1997  and  Wu  et  al.,  1997). 
Edinboro et al., (2004) showed that intran-
asal  vaccines  could  prevent  tracheobronc-
hitis  in  dogs.  These  reports  explain  the 
highly significant increase in the level of Ig 
G in bronchial lavage and nasal bed harvest 
in  the  different  intranasal  bacterial  lysates 
vaccinated  mice,  also  the  significant 
increase in the serum Ig G. These findings 
were  also supported by Kuenen et al., 1994 
who mentioned that the protective effect of 
bacterial  lysates  is  accoimpanied  by 
priming  for  specific  Ig  G  responsiveness. 
Teloni et al. (2004) mentioned that bacterial 
proteins  and  oligodeoxynucle-otides Response Of Mice Tissues To Intranasal Bacterial Lysate ………. 
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applied  intranasally  rised  antibody  classes 
and subclasses. 
         This  study  dealt  with  the  immune 
changes  in  response  to  intranasal  vaccina-
tion  with  Esch.  coli  lysate,  Pseudomonas 
aeroginosa lysate, Salmonella typhi lysate, 
Shigella  flexeneri  lysate,  Staph.  aureus 
lysate and mixed bacterial lysates. Ryan et 
al.  (1999)  mentioned  that  Esch.  coli  heat 
labile  toxin  act  as  effective  mucosal 
adjuvant  for  nasal  delivery  of  acellular 
pertussis  vaccine.  Bennet-Guerrero  et  al., 
(2000)  found  that  active  immunization  of 
mice with complete core LPS of Esch. coli, 
Pseudomonas  aeroginosa  and  Bacteroids 
fragilis mixed  together  to  form  a  cocktail, 
provided  protection  against  a  lethal  chall-
enge with Esch. coli. The vaccine was non 
toxic,  non  pyrogenic  and  immunogenic 
against  a  wide  variety  of  pathogens  found 
clinically.  The  inactivated  bacterial  lysates 
used in this study, in the given dose, proved 
to  be  non-  toxic  and  immunostimulant. 
Harrison  et  al.  (1997)  used  Salmonella 
typhimurium vaccine in the murine typhoid 
model.  On  the  other  hand,  this  strain  was 
used by Corthesy-Theulas et al., (1998) for 
protecting  mice  from  Helicobacter  pylori 
infection  by  nasal  immunization.  Furlong 
and  David,  (1996)  mentioned  that  shigella 
liposaccharides  complexes  can  be  used  as 
an  effective  immunogen.  These  proteos-
omes  preparations  induce  an  effective 
mucosal  response  when  delivered  either 
orally  or  intranasally  and  cause  protection 
against  shigella  infections  (  Orr  et  al., 
1993).  O’  Brien  et  al.  (2000)  studied  the 
protective  effect  of  Staph  aureus  lysate. 
Both Rutishauser et al., (1998) and Ruah et 
al.  (2001)  studied  the  immunoprotective 
effect  of  mixed  bacterial  lysates  against 
recurrent respiratory tract infections. 
         In this  study, histological  changes  of 
liver,  thymus,  spleen,  lung  and  bronchi 
showed  morphological  differences  depen-
ding  on  the  type  of  vaccine  used. 
Preparations  were  characterized  by 
stimulating  effect  on  reticuloendothelial 
system, which  was much  pronounced  after 
giving mixed bacterial lysates. Haschek and 
Rouseaux,  (1998)  mentioned  that  the 
morphological response can  be considered 
as involution  of  lymphoid organs  were  the 
thymus  being  very  susceptible  to  toxic 
injury  and  also  hyperplasia  occurred. 
Bacterial  endotoxins  can  induce  mild 
hepatic  inflammation  and  varying  degrees 
of hepatcellular cholestasis. The later effect 
is  attributed  to  the  effects  of  proinf-
lammatory  cytokines,  released  by  Kupffer 
cells  and  endothelial  cells  in  response  to 
circulating endotoxin (Cotran et al., 1999). 
Trauner  et  al.  (1999)  illustrated  that 
intrahepatic  cholestasis  (  inflammation-
induced  cholestasis)  is  induced  by  inflam-
matory  cytokines  in  response  to  various 
infectious  stimuli  causing  liver  oedema, 
ballooning  and  cellular  infiltration.  These 
cytokine  effects  are  reversible  and  bile 
secreting function is restored upon disappe-
arance  of  the  inflammatory  injury.  In  this 
study,  liver  inflammatory  response  to 
bacterial lysates was clear when Salmonella 
typhi  lysate,  Pseudomonas  aeroginosa 
lysate, Shigella flexeneri lysate and Staph. 
aureus  lysate  were  used.  Sakiri  et  al., 
(1998)  stated  that    shigella  toxins  caused 
tissue damage and vascular lesions in which 
endothelial cells were swollen and detached 
from  underlying  basement  membranes. 
They  showed  also  that  these  vascular 
changes occur in the presence of proinflam-
matory  cytokines  tumor  necrosis  factor- 
alpha (TNF- α) or interleukin –1 beta (IL- 1 
β).  Liver  sections  in  this  study  illustrated 
liver  cell  damage  changes  and  vascular 
lesions  and  congestion  in  response  to 
Shigella  flexeneri  lysate.  Polotskii  et  al., 
(1981) said that shigella lysates caused  an 
increased  number  of  cellular  lymphocytic 
infiltration.  This  observation  was  recorded 
in  this  study  in  liver  sections,  spleen, 
thymus and lung tissue. The spleen of mice  
that received Shig. flexeneri lysate sections 
showed red pulp contained aggregations of 
large nuclei varying considerably in size  , 
heavy  lymphocytic  infiltration  of  mature 
lymphocytes,  plasma  cells  and  macrop-
hages  in  red  pulp  (Fig.  2-6).The  thymus 
gland  section  obtained  from  animals  recei-
ved Shigella  flexeneri lysate  showed  some 
vaculated cells in medulla  and  cortex,  also  
bizarre    cells      or    their  debris  could  be 
detected. 
         Respiratory  tract  histopathological 
study revealed increased cellular infiltration Hanaa A. Mansour 
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of  polymorphonuclear  leucocytes  (PMNs) 
and  monocytes  in  response  to  bacterial 
lysates , these infiltrates were also detected 
in  bronchoalveolar  fluid.  Wagner  et  al, 
(1999)  mentioned  that  bronchoalveolar 
lavage  (BALF)-  PMN  accumulation  in 
response  to  intratracheal  treatment  with 
LPS  was  100%.  In  contrast,  intravenous 
endotoxemia  inhibited  pulmonary  PMN 
migration. Fan et al. (1998) showed that in 
a  rodent  model,  animals  exposed  to 
antecedent shock exhibited augmented lung 
inflammation  in  response  to  LPS  resuscit-
ated shock where enhanced lung neutrophil 
sequestration  and  transpulmonary  albumin 
flux in response to intratracheal LPS. They 
mentioned  that  primed  alveolar  macrop-
hages  play  a  major  role  in  enhanced  lung 
leucosequestration and transpulmonary flux 
in  response  to  LPS  following  resuscitated 
shock.  Both  Mmin  et  al  (1979)  and  van 
Daal  et  al.  (1992)  showed  that  polyvalent 
bacterial  lysates  could  protect  against 
respiratory  diseases.  They  showed  that 
immunization with bacterial lysates reduced 
the  intrapulmonary  inflammatory  reaction 
to infection, that was assessed by measure-
ment of PMN elastase in BALF. 
        This  study  concludes  that  immuniz-
ation through the nasal route is an adequate  
and  efficient  method  of  vaccine  delivery, 
this  route  also  offered  effective  priming  . 
Bacterial  lysates  play  a  role  as  immuno-
stimulant-  immunomodulator  vaccines. 
Further studies are needed to establish safe 
limits of endotoxins in vaccines in different 
animal models  ( Mader et al., 1997 ). Also, 
more studies should be carried out to assess 
lung injury by priming for an exagg-erated 
response to a second stimulus, the so-called 
“ two-hit “ hypothesis (Fan et al., 1998). 
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 ٍجىنىكبيربفنا خجعش ( خعبًُنا  و خُجطنا بُجىنىُثوركًُنا حدحو )  
   خُئاودنا سىحجنا و خثبقرهن خُيىقنا خئُهنا .  
 
            هبمم ُجنا ةربمم زنا ٌارممئا ًممهع خمم اردنا ِرمما هارممجا ىممر  خممَُبًص  دممع ًممند بهًُمماقر ىممر ًممزنا و
 ىمر دمقا خمُنبزنا دبمعىً ًنا بميأ ،خطثبض خُعُجط خعىً ًك ًنولأا خعىً ًنا رجزعر شُح دبعىً ي
ًنبزنبك ًا و فَلأا قَرط ٍع بهًُعطر  :  خَرُزكجنا دلاهحزًهن ميبحنا لىهحًنا ( ىجُ لاث  ) –    مهحزًنا
ي ىمممك بُممميَرُيَأ ٌرمممُزكجنا -   و ىممم  يرمممُزكجنا ممممهحزًنا ا ىمممُُجورَأ سبَىي -   -    يرمممُزكجنا ممممهحزًنا
ًفَبممر لاَُىًنبمم  -   -   يارُُُمماكُها لاُ ُممش يرممُزكجنا مممهحزًنا -   -    سبكىكىهُابزمم  يرممُزكجنا مممهحزًنا
سىَروأ -   -   خقثبانا خَرُزكجنا  عاىَلأا طىهخًن يرُزكجنا مهحزًنا .  
ًمهع فمَلأا قَرط ٍع خَرُزكجنا دلاهحزًنبث ىُعطزنا حردق خ اردنا ِرا ذزجصأ   د  يىمُعي رمُُير سادمح
 بمَلاخهن خمَىئًنا خجماُنا ًما و هبم ُجنا ودمنا داركن ٍعىُنا دعنا و هب ُجنا ودنا داركن ًهكنا دعنا ًا
ىظعنا عبخُث خَوبفًُهنا  .  ح بم ًنا وبماجلأا خجماَ  ح بمَةث يىمُعي رمُُير سودمح ٍُمجر كنرك G     كنرمك
 و خُم ىًُضنا حدينا و لبحطنا ٌا وأ ًا خَىُعي دارُير درهظ   سودمح دارمُيزنا ِرما تحبما دمق د  
خُئاىهنا دبجُعينا و خئرنا و خُ ىًُضنا حدينا و لبحطنا و دجكنا خ اَأ ًا خَىهخ خطيَأ و دبالازخ .  
           خممَرُزكجنا دلاهحزًنبمث ىُممعطزهن خجحبمطًنا خممفهزخًنا دارمُيزنا ٌأ خمم اردنا ِرما ٍممي  هخزماَ
 بهيادخز لأ دبًُعطزنا ِرا حشرَ فَلأا قَرط ٍع ًعبًُنا  به نا ةُفحزن  خج بُي خهُ ىك .  
 
 